Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an announcement.
Microba Life Sciences Limited announced the release of its Q3 FY25 Quarterly Activities Report and Investor Presentation, scheduled for April 30, 2025. The company will also provide a video presentation by CEO Dr. Luke Reid, accessible through its Investor Hub, allowing stakeholders to engage and submit questions. This initiative underscores Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is a precision microbiome company focused on improving human health. Utilizing advanced technology to measure the human gut microbiome, the company is involved in discovering and developing novel therapeutics for chronic diseases and offers gut microbiome testing services globally to researchers, clinicians, and consumers. Through collaborations with leading organizations, Microba is exploring new connections between the microbiome, health, and disease to create innovative health solutions.
YTD Price Performance: -7.69%
Average Trading Volume: 189,810
Technical Sentiment Signal: Buy
Current Market Cap: A$80.61M
Find detailed analytics on MAP stock on TipRanks’ Stock Analysis page.